安进收购Horizon的三款药物依旧表现不佳

动脉网
May 02, 2025

安进以278亿美元收购Horizon Therapeutics的三款药物Uplizna、Krystexxa和Tepezza后,这些药物的销售表现一直不佳。一季度财报显示,这三款药物的销售额均低于分析师预期,且环比出现两位数下滑。具体来看,Uplizna销售额为9100万美元,比预期低2000万美元;Krystexxa销售额为2.36亿美元,比预期低5700万美元;Tepezza销售额为3.81...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10